Posters/Publications
paper
Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Clinical Cancer Research
Date -
04/2023
paper
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
Scientific Reports
Date -
09/2022
paper
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
Nature Communications
Date -
07/2022
poster
A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study
EASL International Liver Congress
Date -
06/2022